H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on PRQR stock, giving a Buy rating on April 29.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Andrew Fein has given his Buy rating due to a combination of factors related to ProQR’s innovative RNA editing platform and its potential to address significant unmet medical needs. The upcoming AX-0810 program, which targets genetically validated diseases, is on track to file a CTA in the second quarter of 2025, with promising topline data expected by the fourth quarter of the same year. The program’s focus on bile acid modulation in diseases like PSC, supported by preclinical data and human genetics, suggests a viable therapeutic target that could unlock substantial value.
Moreover, the next-generation AX-0810 has demonstrated a significant increase in potency and improved stability, with no signs of hepatotoxicity or immunostimulatory effects, indicating a favorable safety profile. The Phase 1 study will evaluate changes in bile acid levels, leveraging established target engagement profiles from non-human primate models. These factors, combined with supportive biomarker data and the broader potential of the platform, underpin Fein’s positive outlook on ProQR’s stock.
According to TipRanks, Fein is a 4-star analyst with an average return of 3.1% and a 43.41% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neurocrine, Arvinas Holding Company, and Insmed.
In another report released on April 29, Evercore ISI also initiated coverage with a Buy rating on the stock with a $5.00 price target.